Literature DB >> 10351951

Variable levels of normal RNA in different fetal organs carrying a cystic fibrosis transmembrane conductance regulator splicing mutation.

O Chiba-Falek1, R B Parad, E Kerem, B Kerem.   

Abstract

Disease severity varies among cystic fibrosis (CF) patients carrying the same cystic fibrosis transmembrane conductance regulator (CFTR) genotype and among organs of the same individual. It has been shown that the class V splicing mutation 3849 + 10 kb C--> T produces both normal and aberrantly spliced CFTR transcripts. We analyzed the levels of normal CFTR messenger RNA (mRNA) in different organs of an aborted fetus carrying the 3849 + 10 kb C--> T mutation, and found that they correlated with the histopathologic changes observed in these organs. We performed semiquantitative nondifferential reverse transcription-polymerase chain reaction on several organs from a 22-wk aborted CF fetus carrying the 3849 + 10 kb C--> T mutation. A very low level (1%) of normal CFTR mRNA was detected in the severely affected ileum of this fetus. Higher levels were found in the histopathologically unaffected trachea (17%), colon (19%), and lung (26%). Thus, as early as in utero, the regulation of alternative splice-site selection is an important mechanism underlying variable CF severity. Understanding of the mechanisms regulating alternative splicing in different tissues will contribute to potential therapy for patients carrying splicing mutations in CF and other human disease genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10351951     DOI: 10.1164/ajrccm.159.6.9808012

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  6 in total

Review 1.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

2.  Characterization of a disease-associated mutation affecting a putative splicing regulatory element in intron 6b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Authors:  Valeria Faà; Federica Incani; Alessandra Meloni; Denise Corda; Maddalena Masala; A Maria Baffico; Manuela Seia; Antonio Cao; M Cristina Rosatelli
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

Review 3.  Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Victoria L Campodónico; Mihaela Gadjeva; Catherine Paradis-Bleau; Ahmet Uluer; Gerald B Pier
Journal:  Trends Mol Med       Date:  2008-02-11       Impact factor: 11.951

4.  Spontaneous rescue from cystic fibrosis in a mouse model.

Authors:  Nikoletta Charizopoulou; Martina Wilke; Martina Dorsch; Alice Bot; Huub Jorna; Silke Jansen; Frauke Stanke; Hans J Hedrich; Hugo R de Jonge; Burkhard Tümmler
Journal:  BMC Genet       Date:  2006-03-29       Impact factor: 2.797

5.  Human sperm ion channel (dys)function: implications for fertilization.

Authors:  Sean G Brown; Stephen J Publicover; Christopher L R Barratt; Sarah J Martins da Silva
Journal:  Hum Reprod Update       Date:  2019-11-05       Impact factor: 15.610

6.  Ivacaftor in People with Cystic Fibrosis and a 3849+10kb CT or D1152H Residual Function Mutation.

Authors:  Eitan Kerem; Malena Cohen-Cymberknoh; Reuven Tsabari; Michael Wilschanski; Joel Reiter; David Shoseyov; Alex Gileles-Hillel; Thea Pugatsch; Jane C Davies; Christopher Short; Clare Saunders; Cynthia DeSouza; James C Sullivan; Jamie R Doyle; Keval Chandarana; Nils Kinnman
Journal:  Ann Am Thorac Soc       Date:  2021-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.